Compositions and methods for delivery of ocular therapeutics
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsEric Andrew Appel, Emily Louise Meany
Life of this patent
Estimating the term…
Abstract
Compositions for treating ocular disease are disclosed herein. In some embodiments, the composition comprises a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles. The dynamic hydrogel can also comprise an ocular therapeutic encapsulated by the dynamic hydrogel.
Claims21
1-19. (canceled)
A method of treating a disease or condition, the method comprising:
- administering a composition to a subject, wherein the composition comprises:
- a dynamic hydrogel comprising a polymer and a plurality of nanoparticles, wherein the polymer is non-covalently crosslinked with the plurality of nanoparticles, and
- an ocular therapeutic encapsulated by the dynamic hydrogel.
The method of claim 204, wherein the ocular therapeutic comprises bimatoprost, latanoprost, travoprost, tafluprost, pilocarpine, atropine, scopolamine, bunolol, metipranolol, propranolol, timolol, betaxolol, levobunolol, atenolol, befunolol, metoprolol, acetazolamide, dorzolamide, brinzolamide, methazolamide, dichlorphenamide, diamox, apraclonidine, brimonidine, dipivefrine, guanethidine, dapiprazole, pegaptanib sodium, ranibizumab, aflibercept, brolucizumab, or faricimab.
Dependencies are inferred from the claim text.